ONTAK
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Lymphoma, T-Cell, Cutaneous
Conditions
Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides, Sezary Syndrome
Trial Timeline
Jun 1, 1995 → Dec 1, 2006
NCT ID
NCT00050999About ONTAK
ONTAK is a approved stage product being developed by Eisai for Lymphoma, T-Cell, Cutaneous. The current trial status is completed. This product is registered under clinical trial identifier NCT00050999. Target conditions include Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides, Sezary Syndrome.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00726037 | Phase 2 | Terminated |
| NCT00055146 | Phase 2 | Completed |
| NCT00051025 | Phase 2 | Completed |
| NCT00051012 | Approved | Completed |
| NCT00050999 | Approved | Completed |
Competing Products
20 competing products in Lymphoma, T-Cell, Cutaneous